Real‐World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease‐Modifying Therapy in Pediatric Multiple Sclerosis

To assess real-world effectiveness of switching disease-modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity. Of 2615 pediatric-onset demyelinating disease patients at 12 clinics in the Uni...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of neurology
Hauptverfasser: Abrams, Aaron W., Waltz, Michael, Casper, T. Charles, Aaen, Gregory, Benson, Leslie A., Bernfeld, Eva‐Chava M., Charvet, Leigh E., Chitnis, Tanuja, Francisco, Carla, Gorman, Mark P., Graves, Jennifer S., Krupp, Lauren, O'Neill, Kimberly, Lotze, Timothy E., Mar, Soe, Ness, Jayne, Rensel, Mary, Rodriguez, Moses, Rose, John, Rutatangwa, Alice, Schreiner, Teri, Shukla, Nikita, Tillema, Jan‐Mendelt, Weinstock‐Guttman, Bianca, Wheeler, Yolanda, Waubant, Emmanuelle, Krysko, Kristen M.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 06.11.2025
ISSN:0364-5134, 1531-8249, 1531-8249
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract To assess real-world effectiveness of switching disease-modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity. Of 2615 pediatric-onset demyelinating disease patients at 12 clinics in the United States (US) Network of Pediatric MS Centers, those with MS/CIS on initial therapy with a platform injectable who switched to another class of platform injectable, oral or infusion DMT were analyzed. Relapse rate was modeled with negative binomial regression, adjusted for preidentified confounders. A total of 212 children switched DMT before age 18 (67% female, 95% MS). Ninety-three switched from injectable to injectable, 76 injectable to oral, and 43 injectable to infusion. Switchers to oral or infusion were older at onset (injectable 12.3 years, oral 13.5 years, and infusion 14.2 years) and switch (injectable 14.6 years, oral 16.0 years, and infusion 15.7 years). Switchers to infusion DMT were more likely to have enhancing lesions (injectable 45%, oral 28%, and infusion 67%). Compared to injectable (annualized relapse rate [ARR] = 0.88, 95% confidence interval [CI] = 0.52-1.48), relapse rates were lower for injectable to oral (ARR = 0.34, 95% CI = 0.20-0.57; rate ratio: 0.38, 95% CI = 0.21-0.69) and injectable to infusion (ARR = 0.18, 95% CI = 0.09-0.37; rate ratio: 0.21, 95% CI = 0.10-0.44) (p < 0.001). Adjusted number needed to treat in person-years to prevent 1 relapse with oral over injectable was 1.84 (95% CI = 1.03-8.69) and infusion over injectable 1.43 (95% CI = 1.00-3.88). Switching from platform injectable to oral or infusion compared to other platform injectable DMT led to better disease control in pediatric MS. Long-term safety data are required. ANN NEUROL 2025.
AbstractList To assess real-world effectiveness of switching disease-modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity.OBJECTIVETo assess real-world effectiveness of switching disease-modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity.Of 2615 pediatric-onset demyelinating disease patients at 12 clinics in the United States (US) Network of Pediatric MS Centers, those with MS/CIS on initial therapy with a platform injectable who switched to another class of platform injectable, oral or infusion DMT were analyzed. Relapse rate was modeled with negative binomial regression, adjusted for preidentified confounders.METHODSOf 2615 pediatric-onset demyelinating disease patients at 12 clinics in the United States (US) Network of Pediatric MS Centers, those with MS/CIS on initial therapy with a platform injectable who switched to another class of platform injectable, oral or infusion DMT were analyzed. Relapse rate was modeled with negative binomial regression, adjusted for preidentified confounders.A total of 212 children switched DMT before age 18 (67% female, 95% MS). Ninety-three switched from injectable to injectable, 76 injectable to oral, and 43 injectable to infusion. Switchers to oral or infusion were older at onset (injectable 12.3 years, oral 13.5 years, and infusion 14.2 years) and switch (injectable 14.6 years, oral 16.0 years, and infusion 15.7 years). Switchers to infusion DMT were more likely to have enhancing lesions (injectable 45%, oral 28%, and infusion 67%). Compared to injectable (annualized relapse rate [ARR] = 0.88, 95% confidence interval [CI] = 0.52-1.48), relapse rates were lower for injectable to oral (ARR = 0.34, 95% CI = 0.20-0.57; rate ratio: 0.38, 95% CI = 0.21-0.69) and injectable to infusion (ARR = 0.18, 95% CI = 0.09-0.37; rate ratio: 0.21, 95% CI = 0.10-0.44) (p < 0.001). Adjusted number needed to treat in person-years to prevent 1 relapse with oral over injectable was 1.84 (95% CI = 1.03-8.69) and infusion over injectable 1.43 (95% CI = 1.00-3.88).RESULTSA total of 212 children switched DMT before age 18 (67% female, 95% MS). Ninety-three switched from injectable to injectable, 76 injectable to oral, and 43 injectable to infusion. Switchers to oral or infusion were older at onset (injectable 12.3 years, oral 13.5 years, and infusion 14.2 years) and switch (injectable 14.6 years, oral 16.0 years, and infusion 15.7 years). Switchers to infusion DMT were more likely to have enhancing lesions (injectable 45%, oral 28%, and infusion 67%). Compared to injectable (annualized relapse rate [ARR] = 0.88, 95% confidence interval [CI] = 0.52-1.48), relapse rates were lower for injectable to oral (ARR = 0.34, 95% CI = 0.20-0.57; rate ratio: 0.38, 95% CI = 0.21-0.69) and injectable to infusion (ARR = 0.18, 95% CI = 0.09-0.37; rate ratio: 0.21, 95% CI = 0.10-0.44) (p < 0.001). Adjusted number needed to treat in person-years to prevent 1 relapse with oral over injectable was 1.84 (95% CI = 1.03-8.69) and infusion over injectable 1.43 (95% CI = 1.00-3.88).Switching from platform injectable to oral or infusion compared to other platform injectable DMT led to better disease control in pediatric MS. Long-term safety data are required. ANN NEUROL 2025.INTERPRETATIONSwitching from platform injectable to oral or infusion compared to other platform injectable DMT led to better disease control in pediatric MS. Long-term safety data are required. ANN NEUROL 2025.
To assess real-world effectiveness of switching disease-modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity. Of 2615 pediatric-onset demyelinating disease patients at 12 clinics in the United States (US) Network of Pediatric MS Centers, those with MS/CIS on initial therapy with a platform injectable who switched to another class of platform injectable, oral or infusion DMT were analyzed. Relapse rate was modeled with negative binomial regression, adjusted for preidentified confounders. A total of 212 children switched DMT before age 18 (67% female, 95% MS). Ninety-three switched from injectable to injectable, 76 injectable to oral, and 43 injectable to infusion. Switchers to oral or infusion were older at onset (injectable 12.3 years, oral 13.5 years, and infusion 14.2 years) and switch (injectable 14.6 years, oral 16.0 years, and infusion 15.7 years). Switchers to infusion DMT were more likely to have enhancing lesions (injectable 45%, oral 28%, and infusion 67%). Compared to injectable (annualized relapse rate [ARR] = 0.88, 95% confidence interval [CI] = 0.52-1.48), relapse rates were lower for injectable to oral (ARR = 0.34, 95% CI = 0.20-0.57; rate ratio: 0.38, 95% CI = 0.21-0.69) and injectable to infusion (ARR = 0.18, 95% CI = 0.09-0.37; rate ratio: 0.21, 95% CI = 0.10-0.44) (p < 0.001). Adjusted number needed to treat in person-years to prevent 1 relapse with oral over injectable was 1.84 (95% CI = 1.03-8.69) and infusion over injectable 1.43 (95% CI = 1.00-3.88). Switching from platform injectable to oral or infusion compared to other platform injectable DMT led to better disease control in pediatric MS. Long-term safety data are required. ANN NEUROL 2025.
Author Wheeler, Yolanda
Casper, T. Charles
Weinstock‐Guttman, Bianca
Aaen, Gregory
Charvet, Leigh E.
Mar, Soe
Rensel, Mary
Abrams, Aaron W.
Krysko, Kristen M.
Graves, Jennifer S.
Gorman, Mark P.
Krupp, Lauren
Ness, Jayne
Lotze, Timothy E.
Waltz, Michael
Rose, John
Schreiner, Teri
Chitnis, Tanuja
Francisco, Carla
Tillema, Jan‐Mendelt
Bernfeld, Eva‐Chava M.
O'Neill, Kimberly
Rutatangwa, Alice
Waubant, Emmanuelle
Shukla, Nikita
Benson, Leslie A.
Rodriguez, Moses
Author_xml – sequence: 1
  givenname: Aaron W.
  orcidid: 0000-0002-4607-5740
  surname: Abrams
  fullname: Abrams, Aaron W.
  organization: Department of Neurology Cleveland Clinic Cleveland OH
– sequence: 2
  givenname: Michael
  surname: Waltz
  fullname: Waltz, Michael
  organization: Department of Pediatrics University of Utah Salt Lake City UT
– sequence: 3
  givenname: T. Charles
  surname: Casper
  fullname: Casper, T. Charles
  organization: Department of Pediatrics University of Utah Salt Lake City UT
– sequence: 4
  givenname: Gregory
  surname: Aaen
  fullname: Aaen, Gregory
  organization: Department of Pediatrics Loma Linda University San Bernardino CA
– sequence: 5
  givenname: Leslie A.
  surname: Benson
  fullname: Benson, Leslie A.
  organization: Department of Neurology Boston Children's Hospital Boston MA
– sequence: 6
  givenname: Eva‐Chava M.
  surname: Bernfeld
  fullname: Bernfeld, Eva‐Chava M.
  organization: Department of Neurology Cleveland Clinic Cleveland OH
– sequence: 7
  givenname: Leigh E.
  orcidid: 0000-0003-4429-9713
  surname: Charvet
  fullname: Charvet, Leigh E.
  organization: Department of Neurology New York University Langone Health New York NY
– sequence: 8
  givenname: Tanuja
  surname: Chitnis
  fullname: Chitnis, Tanuja
  organization: Department of Pediatric Neurology Massachusetts General Hospital Boston MA
– sequence: 9
  givenname: Carla
  surname: Francisco
  fullname: Francisco, Carla
  organization: Department of Neurology University of California San Francisco CA
– sequence: 10
  givenname: Mark P.
  surname: Gorman
  fullname: Gorman, Mark P.
  organization: Department of Neurology Boston Children's Hospital Boston MA
– sequence: 11
  givenname: Jennifer S.
  surname: Graves
  fullname: Graves, Jennifer S.
  organization: Department of Neurology University of California, San Diego La Jolla CA
– sequence: 12
  givenname: Lauren
  orcidid: 0000-0001-7003-807X
  surname: Krupp
  fullname: Krupp, Lauren
  organization: Department of Neurology New York University Langone Health New York NY
– sequence: 13
  givenname: Kimberly
  orcidid: 0000-0001-6021-8683
  surname: O'Neill
  fullname: O'Neill, Kimberly
  organization: Department of Neurology New York University Langone Health New York NY
– sequence: 14
  givenname: Timothy E.
  surname: Lotze
  fullname: Lotze, Timothy E.
  organization: Department of Neurology Texas Children's Hospital Houston TX
– sequence: 15
  givenname: Soe
  surname: Mar
  fullname: Mar, Soe
  organization: Department of Neurology Washington University in Saint Louis St Louis MO
– sequence: 16
  givenname: Jayne
  surname: Ness
  fullname: Ness, Jayne
  organization: Department of Pediatrics University of Alabama at Birmingham Birmingham AL
– sequence: 17
  givenname: Mary
  surname: Rensel
  fullname: Rensel, Mary
  organization: Department of Neurology Cleveland Clinic Cleveland OH
– sequence: 18
  givenname: Moses
  surname: Rodriguez
  fullname: Rodriguez, Moses
  organization: Department of Neurology Mayo Clinic Rochester MN
– sequence: 19
  givenname: John
  surname: Rose
  fullname: Rose, John
  organization: Department of Neurology University of Utah Salt Lake City UT
– sequence: 20
  givenname: Alice
  surname: Rutatangwa
  fullname: Rutatangwa, Alice
  organization: Department of Neurology University of California San Francisco CA
– sequence: 21
  givenname: Teri
  surname: Schreiner
  fullname: Schreiner, Teri
  organization: Department of Neurology and Pediatrics University of Colorado Aurora CO
– sequence: 22
  givenname: Nikita
  surname: Shukla
  fullname: Shukla, Nikita
  organization: Department of Pediatrics and Neurology Dell Children's Hospital, University of Texas Austin TX
– sequence: 23
  givenname: Jan‐Mendelt
  surname: Tillema
  fullname: Tillema, Jan‐Mendelt
  organization: Department of Neurology Mayo Clinic Rochester MN
– sequence: 24
  givenname: Bianca
  surname: Weinstock‐Guttman
  fullname: Weinstock‐Guttman, Bianca
  organization: Department of Neurology State University of New York at Buffalo Buffalo NY
– sequence: 25
  givenname: Yolanda
  surname: Wheeler
  fullname: Wheeler, Yolanda
  organization: Department of Nursing University of Alabama at Birmingham Birmingham AL
– sequence: 26
  givenname: Emmanuelle
  orcidid: 0000-0001-5188-0157
  surname: Waubant
  fullname: Waubant, Emmanuelle
  organization: Department of Neurology University of California San Francisco CA
– sequence: 27
  givenname: Kristen M.
  orcidid: 0000-0003-0090-597X
  surname: Krysko
  fullname: Krysko, Kristen M.
  organization: Division of Neurology, Department of Medicine BARLO MS Centre, St. Michael's Hospital, Li Ka Shing Knowledge Institute, University of Toronto Toronto Canada
BackLink https://www.ncbi.nlm.nih.gov/pubmed/41195640$$D View this record in MEDLINE/PubMed
BookMark eNo9kc1OHDEQhK0IFBaSQ14A-ZgcBtrjsWd9jPiXQESBJMeRx9MORl57sWeC9saVG8_Ik2D-cmqV9FVJXbVJ1kIMSMgXBjsMoN7VQe-0c5jLD2TGBGfVvG7UGpkBl00lGG82yGbO1wCgJIOPZKNhTAnZwIzc_0TtH-8e_sTkB3pgLZrR_cOAOdNo6cWtG82VC3_pGOl50p7GRE-CnbKLgf7GlKdc9HVx6d4j3XcZdcYSeBYHZ1fPzssrTHq5oi7QHzg4PSZn6NnkR7csjgvjMcXs8ieybrXP-PntbpFfhweXe8fV6fnRyd7308rUDMaqNwJbAK2U5I1tGVqOZtCiloIJnIOVojeq1b0SVjCrJTAheqg1G1ozlHa2yNfX3GWKNxPmsVu4bNB7HTBOueO1VJxzpVRBt9_QqV_g0C2TW-i06t7rK8C3V8CUF3JC-x9h0D1P05Vpupdp-BO6loRd
Cites_doi 10.1016/j.ejpn.2023.06.011
10.1007/s10072-022-06211-8
10.1016/j.msard.2023.104962
10.7224/1537-2073.2019-095
10.1056/NEJMoa1601277
10.1212/WNL.0000000000006471
10.1016/S2352-4642(24)00047-6
10.1002/ana.25737
10.1177/0883073814550656
10.1007/s10072-022-06431-y
10.1007/978-1-4614-1353-0
10.1016/j.msard.2023.104942
10.1016/j.ejpn.2023.05.001
10.1001/jamaneurol.2023.5566
10.1016/S1474-4422(17)30470-2
10.1001/archneurol.2008.505
10.3389/fneur.2022.824926
10.1093/brain/awp278
10.1007/s00415-024-12610-y
10.1002/pst.1650
10.1056/NEJMoa044397
10.1007/s00210-022-02238-y
10.1177/0883073819845827
10.3389/fnins.2023.1259306
10.1212/WNL.0000000000208114
10.1177/0962280209105023
10.1111/ene.16228
10.1002/ana.22366
10.1212/NXI.0000000000200303
10.1212/WNL.0000000000007647
10.1371/journal.pone.0085741
10.1056/NEJMoa1800149
10.1002/9780470316696
10.1177/1352458513484547
10.1016/j.msard.2019.101431
10.1016/j.msard.2021.103277
10.17116/jnevro2023123092100
10.1212/NXI.0000000000001008
ContentType Journal Article
Copyright 2025 The Author(s). Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Copyright_xml – notice: 2025 The Author(s). Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
CorporateAuthor the US Network of Pediatric MS Centers
US Network of Pediatric MS Centers
CorporateAuthor_xml – name: the US Network of Pediatric MS Centers
– name: US Network of Pediatric MS Centers
DBID AAYXX
CITATION
NPM
7X8
DOI 10.1002/ana.78086
DatabaseName CrossRef
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1531-8249
ExternalDocumentID 41195640
10_1002_ana_78086
Genre Journal Article
GrantInformation_xml – fundername: National Multiple Sclerosis Society
  grantid: HC-1509-06233
GroupedDBID ---
.3N
.GA
05W
0R~
10A
1L6
1OB
1OC
1ZS
23M
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
5GY
5VS
66C
6J9
6P2
6PF
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAMMB
AAMNL
AANLZ
AAONW
AAWTL
AAXRX
AAYCA
AAYXX
AAZKR
ABCQN
ABCUV
ABIJN
ABIVO
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBMB
ACCZN
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEFGJ
AEGXH
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFAZI
AFBPY
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AGHNM
AGXDD
AGYGG
AHBTC
AHMBA
AIACR
AIAGR
AIDQK
AIDYY
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
CITATION
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR1
DR2
DRFUL
DRMAN
DRSTM
EBS
F00
F01
F04
F5P
F8P
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HGLYW
HHY
HHZ
HZ~
IX1
J0M
JPC
KBYEO
KD1
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LXL
LXN
LXY
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O8X
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.-
Q.N
Q11
QB0
QRW
R.K
ROL
RX1
SJN
SUPJJ
TEORI
UB1
V2E
V8K
V9Y
W8V
W99
WBKPD
WH7
WHWMO
WIB
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WVDHM
WXI
WXSBR
XG1
XPP
XSW
XV2
YOC
ZRF
ZRR
ZZTAW
~IA
~WT
NPM
7X8
ID FETCH-LOGICAL-c210t-bc5e700a99634f71ef3ecda526515e80f65bc97ab95f51fa60155b02a1d7cd153
ISICitedReferencesCount 0
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001609443600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0364-5134
1531-8249
IngestDate Thu Nov 06 18:47:42 EST 2025
Fri Nov 07 01:53:47 EST 2025
Sat Nov 29 06:54:22 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License 2025 The Author(s). Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c210t-bc5e700a99634f71ef3ecda526515e80f65bc97ab95f51fa60155b02a1d7cd153
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-6021-8683
0000-0003-4429-9713
0000-0001-5188-0157
0000-0001-7003-807X
0000-0003-0090-597X
0000-0002-4607-5740
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ana.78086
PMID 41195640
PQID 3269333999
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3269333999
pubmed_primary_41195640
crossref_primary_10_1002_ana_78086
PublicationCentury 2000
PublicationDate 2025-11-06
2025-Nov-06
20251106
PublicationDateYYYYMMDD 2025-11-06
PublicationDate_xml – month: 11
  year: 2025
  text: 2025-11-06
  day: 06
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Annals of neurology
PublicationTitleAlternate Ann Neurol
PublicationYear 2025
References e_1_2_9_30_1
e_1_2_9_31_1
Gorman MP (e_1_2_9_3_1) 2009; 66
e_1_2_9_34_1
Sandesjö F (e_1_2_9_11_1) 2021; 56
e_1_2_9_35_1
e_1_2_9_13_1
Rubin DB (e_1_2_9_23_1) 1987
e_1_2_9_32_1
Erdal JL (e_1_2_9_10_1) 2020; 37
e_1_2_9_12_1
e_1_2_9_33_1
Greenberg B (e_1_2_9_40_1) 2021; 23
Casper TC (e_1_2_9_19_1) 2015; 30
e_1_2_9_15_1
e_1_2_9_38_1
e_1_2_9_39_1
e_1_2_9_17_1
Krupp LB (e_1_2_9_20_1) 2013; 19
e_1_2_9_36_1
McKay KA (e_1_2_9_6_1) 2019; 92
e_1_2_9_16_1
e_1_2_9_37_1
e_1_2_9_18_1
Yang JH (e_1_2_9_7_1) 2022; 13
e_1_2_9_22_1
e_1_2_9_24_1
e_1_2_9_8_1
e_1_2_9_5_1
Zhang Z (e_1_2_9_26_1) 2010; 19
e_1_2_9_4_1
Baroncini D (e_1_2_9_14_1) 2019; 25
Jeong A (e_1_2_9_2_1) 2019; 34
Vittinghoff E (e_1_2_9_25_1) 2012
Polman CH (e_1_2_9_21_1) 2011; 69
e_1_2_9_28_1
Krysko KM (e_1_2_9_9_1) 2020; 88
e_1_2_9_27_1
e_1_2_9_29_1
References_xml – ident: e_1_2_9_16_1
  doi: 10.1016/j.ejpn.2023.06.011
– ident: e_1_2_9_32_1
  doi: 10.1007/s10072-022-06211-8
– ident: e_1_2_9_39_1
  doi: 10.1016/j.msard.2023.104962
– volume: 23
  start-page: 101
  year: 2021
  ident: e_1_2_9_40_1
  article-title: Utilization and treatment patterns of disease‐modifying therapy in pediatric patients with multiple sclerosis in the United States
  publication-title: Int J MS Care
  doi: 10.7224/1537-2073.2019-095
– ident: e_1_2_9_28_1
  doi: 10.1056/NEJMoa1601277
– volume: 25
  start-page: 399
  year: 2019
  ident: e_1_2_9_14_1
  article-title: Long‐term follow‐up of pediatric MS patients starting treatment with injectable first‐line agents: a multicentre, Italian, retrospective, observational study [published correction appears in Mult Scler. 2019 Oct;25(11):NP33]
  publication-title: Mult Scler
– ident: e_1_2_9_29_1
  doi: 10.1212/WNL.0000000000006471
– ident: e_1_2_9_37_1
  doi: 10.1016/S2352-4642(24)00047-6
– volume: 88
  start-page: 42
  year: 2020
  ident: e_1_2_9_9_1
  article-title: Real‐world effectiveness of initial disease‐modifying therapies in pediatric multiple sclerosis
  publication-title: Ann Neurol
  doi: 10.1002/ana.25737
– volume: 30
  start-page: 1381
  year: 2015
  ident: e_1_2_9_19_1
  article-title: The US network of pediatric multiple sclerosis centers: development, progress, and next steps
  publication-title: J Child Neurol
  doi: 10.1177/0883073814550656
– ident: e_1_2_9_18_1
  doi: 10.1007/s10072-022-06431-y
– volume-title: Regression methods in biostatistics
  year: 2012
  ident: e_1_2_9_25_1
  doi: 10.1007/978-1-4614-1353-0
– ident: e_1_2_9_13_1
  doi: 10.1016/j.msard.2023.104942
– ident: e_1_2_9_15_1
  doi: 10.1016/j.ejpn.2023.05.001
– ident: e_1_2_9_17_1
  doi: 10.1001/jamaneurol.2023.5566
– ident: e_1_2_9_22_1
  doi: 10.1016/S1474-4422(17)30470-2
– volume: 66
  start-page: 54
  year: 2009
  ident: e_1_2_9_3_1
  article-title: Increased relapse rate in pediatric‐onset compared with adult‐onset multiple sclerosis
  publication-title: Arch Neurol
  doi: 10.1001/archneurol.2008.505
– volume: 13
  year: 2022
  ident: e_1_2_9_7_1
  article-title: Therapeutic advances in multiple sclerosis
  publication-title: Front Neurol
  doi: 10.3389/fneur.2022.824926
– ident: e_1_2_9_5_1
  doi: 10.1093/brain/awp278
– ident: e_1_2_9_35_1
  doi: 10.1007/s00415-024-12610-y
– ident: e_1_2_9_24_1
  doi: 10.1002/pst.1650
– ident: e_1_2_9_27_1
  doi: 10.1056/NEJMoa044397
– ident: e_1_2_9_33_1
  doi: 10.1007/s00210-022-02238-y
– volume: 34
  start-page: 705
  year: 2019
  ident: e_1_2_9_2_1
  article-title: Epidemiology of pediatric‐onset multiple sclerosis: a systematic review of the literature
  publication-title: J Child Neurol
  doi: 10.1177/0883073819845827
– ident: e_1_2_9_31_1
  doi: 10.3389/fnins.2023.1259306
– ident: e_1_2_9_34_1
  doi: 10.1212/WNL.0000000000208114
– volume: 19
  start-page: 53
  year: 2010
  ident: e_1_2_9_26_1
  article-title: Interval censoring
  publication-title: Stat Methods Med Res
  doi: 10.1177/0962280209105023
– ident: e_1_2_9_30_1
  doi: 10.1111/ene.16228
– volume: 69
  start-page: 292
  year: 2011
  ident: e_1_2_9_21_1
  article-title: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
  publication-title: Ann Neurol
  doi: 10.1002/ana.22366
– ident: e_1_2_9_36_1
  doi: 10.1212/NXI.0000000000200303
– volume: 92
  start-page: e2764
  year: 2019
  ident: e_1_2_9_6_1
  article-title: Long‐term disability progression of pediatric‐onset multiple sclerosis
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000007647
– ident: e_1_2_9_4_1
  doi: 10.1371/journal.pone.0085741
– ident: e_1_2_9_8_1
  doi: 10.1056/NEJMoa1800149
– volume-title: Multiple imputation for nonresponse in surveys
  year: 1987
  ident: e_1_2_9_23_1
  doi: 10.1002/9780470316696
– volume: 19
  start-page: 1261
  year: 2013
  ident: e_1_2_9_20_1
  article-title: International pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune‐mediated central nervous system demyelinating disorders: revisions to the 2007 definitions
  publication-title: Mult Scler
  doi: 10.1177/1352458513484547
– volume: 37
  year: 2020
  ident: e_1_2_9_10_1
  article-title: Clinical characteristics and use of disease modifying therapy in the nationwide Danish cohort of paediatric onset multiple sclerosis
  publication-title: Mult Scler Relat Disord
  doi: 10.1016/j.msard.2019.101431
– volume: 56
  year: 2021
  ident: e_1_2_9_11_1
  article-title: Current international trends in the treatment of multiple sclerosis in children‐impact of the COVID‐19 pandemic
  publication-title: Mult Scler Relat Disord
  doi: 10.1016/j.msard.2021.103277
– ident: e_1_2_9_38_1
  doi: 10.17116/jnevro2023123092100
– ident: e_1_2_9_12_1
  doi: 10.1212/NXI.0000000000001008
SSID ssj0009610
Score 2.493116
SecondaryResourceType online_first
Snippet To assess real-world effectiveness of switching disease-modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS)...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Title Real‐World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease‐Modifying Therapy in Pediatric Multiple Sclerosis
URI https://www.ncbi.nlm.nih.gov/pubmed/41195640
https://www.proquest.com/docview/3269333999
WOSCitedRecordID wos001609443600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library
  customDbUrl:
  eissn: 1531-8249
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0009610
  issn: 0364-5134
  databaseCode: DRFUL
  dateStart: 19990101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Na9swFBdpO8YuY9_LPoo2xi5FrT9iyzqGtWWHJB0l3XIzsiyBodiZ43SFnfd_78my5IRs0B12MYlIZKP34_l9_h5CH2JBGVhDOj8YRwQs8IRkmVKECy-X8MansiXT-Tqhs1myWLAvg8FP2wtzc03LMrm9Zcv_KmpYA2Hr1tl_ELfbFBbgMwgdriB2uN5J8Jdg-hFTI2Ooia0-0-0pP4rGFE-CyXmhe_OrGlSEWuuY2ZGOna1X8F3HZtqWqlOTviHTKi9MQ9TcsBDoMImb8nE0dVWJ8Czw2i1WmzZvz9HckmduhvHH4KubWM-Y1_AELuDzjV-3g2a3yvrbVIlmNm9BZisF3F7caFDbdbMRzgiitq8v3tLAPkkCw2N6LHfXdnS-4ZDlJT-mifcnXu3ZRXp-NZmk87PF_OPyO9Ejx3Rqvpu_socOAhoxUIkHp5fww56zOTZkFvbulpjKC07c3bbNmb_4KK2tMn-EHnZOBh4bcDxGA1k-QfenXRnFU_SrxwjewgiuFHYYwU2FNUZwVWOLEWwwgnuM4B2M4A4juCixwwi2GMEOI8_Q1fnZ_NNn0s3jICLwvYZkIpLU8zi4yOFIUV-qUIqc6wELfiQTT8VRJhjlGYtU5Csea3s88wLu51TkcIzP0X5ZlfIlwpxSX2SKZzT0R5FULM5CcCzAVhUs4z4fovf2WNOloV1JDcF2kMLZp-3ZD9E7e-ApKEWd6eKlrNarFHwSFoZge7MhemEk4bYZaZLDeOS9usO_X6MHPUbfoP2mXsu36J64aYpVfYj26CI57FDzGwUMk3Y
linkProvider Wiley-Blackwell
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Real-World+Effectiveness+of+Switching+to+Oral+or+Infusion+Versus+Injectable+Disease-Modifying+Therapy+in+Pediatric+Multiple+Sclerosis&rft.jtitle=Annals+of+neurology&rft.au=Abrams%2C+Aaron+W&rft.au=Waltz%2C+Michael&rft.au=Casper%2C+T+Charles&rft.au=Aaen%2C+Gregory&rft.date=2025-11-06&rft.issn=1531-8249&rft.eissn=1531-8249&rft_id=info:doi/10.1002%2Fana.78086&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0364-5134&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0364-5134&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0364-5134&client=summon